K
Kyu Pyo Kim
Researcher at University of Ulsan
Publications - 28
Citations - 1030
Kyu Pyo Kim is an academic researcher from University of Ulsan. The author has contributed to research in topics: Oxaliplatin & Colorectal cancer. The author has an hindex of 13, co-authored 28 publications receiving 812 citations.
Papers
More filters
Journal ArticleDOI
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial
Yong Sang Hong,Byung-Ho Nam,Kyu Pyo Kim,Jeong Eun Kim,Seong Joon Park,Young Suk Park,Joon Oh Park,Sun-Young Kim,Tae You Kim,Jee Hyun Kim,Joong Bae Ahn,Seok Byung Lim,Chang Sik Yu,Jin Cheon Kim,Seong Hyeon Yun,Jong Hoon Kim,Jin-Hong Park,Hee Chul Park,Kyung Hae Jung,Tae Won Kim +19 more
TL;DR: This open-label, multicentre, phase 2, randomised trial aimed to compare the efficacy and safety of adjuvant fluorouracil and leucovorin with that of FOLFOX in patients with locally advanced rectal cancer after preoperative chemoradiotherapy.
Journal ArticleDOI
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Yong Sang Hong,Young Suk Park,Ho Yeong Lim,Jeeyun Lee,Tae Won Kim,Kyu Pyo Kim,Sun Young Kim,Ji Yeon Baek,Jee Hyun Kim,Keun Wook Lee,Ik Joo Chung,Sang-Hee Cho,Kyung Hee Lee,Sang Joon Shin,Hye Jin Kang,Dong Bok Shin,Sook Jung Jo,Jae Won Lee +17 more
TL;DR: The SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer and further investigation is needed to explore its potential when used together with other targeted agents or as adjuvant chemotherapy.
Journal ArticleDOI
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.
Yong Sang Hong,Sun Young Kim,Ji Sung Lee,Byung-Ho Nam,Kyu Pyo Kim,Jeong Eun Kim,Young Suk Park,Joon Oh Park,Ji Yeon Baek,Tae-You Kim,Keun Wook Lee,Joong Bae Ahn,Seok Byung Lim,Chang Sik Yu,Jin Cheon Kim,Seong Hyeon Yun,Jong Hoon Kim,Jin-Hong Park,Hee Chul Park,Kyung Hae Jung,Tae Won Kim +20 more
TL;DR: Adjuvant FOLFOX improved DFS in patients with rectal cancer with ypStage II and III disease after preoperative CRT and may be considered on the basis of the postoperative pathologic stage in those who received preoperativeCRT and TME.
Journal ArticleDOI
What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms
Jooae Choe,Kyung Won Kim,Hyoung Jung Kim,Dong Wook Kim,Kyu Pyo Kim,Seung-Mo Hong,Jin-Sook Ryu,Sree Harsha Tirumani,Katherine M. Krajewski,Nikhil H. Ramaiya +9 more
TL;DR: The role of imaging in the multidisciplinary team approach of pancreatic neuroendocrine neoplasms is discussed and the recent significant changes and controversial issues regarding the diagnosis and management are focused on.
Journal ArticleDOI
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1
Yong Sang Hong,Seung Woo Hong,Seung Mi Kim,Dong Hoon Jin,Jae Sik Shin,Dok Hyun Yoon,Kyu Pyo Kim,Jae-Lyun Lee,Dae Seog Heo,Jung Shin Lee,Tae Won Kim +10 more
TL;DR: Results suggest that bortezomib induces G2-M arrest through ROS-inducible ATM phosphorylation and demonstrate that bortsomib is a potential candidate for further investigations in the treatment for CRC patients.